OVERVIEW OF ACTIVITY
BC remains the most frequently diagnosed cancer in women, and in 2015 it is estimated that the disease culminated in 234,190 new cases and 40,730 deaths in the United States alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with BC has increased substantially, as has the population “at risk” for recurrent disease.

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists.

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of colorectal cancer (CRC).

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY